Immunogen Inc
IMGN
IMGN was delisted on the 9th of February, 2024.
236 hedge funds and large institutions have $1.41B invested in Immunogen Inc in 2021 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 88 increasing their positions, 55 reducing their positions, and 28 closing their positions.
75% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 28
73% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $6.8M
60% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 55
41% more capital invested
Capital invested by funds: $1,000M → $1.41B (+$406M)
9% more funds holding
Funds holding: 217 → 236 (+19)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$24M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.8M |
| 3 |
Millennium Management
New York
|
+$13.1M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$12M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$68.5M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$14.5M |
| 3 |
State Street
Boston,
Massachusetts
|
-$6.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.05M |
| 5 |
BlackRock
New York
|
-$3.22M |
IMGN Hedge Fund Activity: Q4 2021 in Review
236 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q4 2021, worth a combined $1.41B — up 41% from $1,000M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new IMGN positions and 28 closed out — a net gain of 21 holders — while 88 added to existing stakes and 55 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $24M. The largest seller was OrbiMed, cutting an estimated $68.5M.
- 236 institutional investors held Immunogen Inc (IMGN) as of Q4 2021, up from 217 in Q3 2021.
- Funds reported $1.41B of Immunogen Inc stock for Q4 2021, up 41% quarter-over-quarter.
- 49 funds opened new Immunogen Inc positions in Q4 2021 and 28 closed out, a net change of +21 holders.
- The largest Immunogen Inc buyer in Q4 2021 was Woodline Partners, an estimated $24M added.
- The largest Immunogen Inc seller in Q4 2021 was OrbiMed, an estimated $68.5M sold.
Based on aggregated 13F filings for Q4 2021.